U.S. Unfractionated Heparin - Uses, Interactions, Mechanism of Action, Market Share Touch US$ 501.5 Million by the End of 2027 | Latest CMI Insights 2021
U.S. Unfractionated Heparin Market Analysis
Overview
As the number of people suffering from venous thromboembolism (VTE) rises, the market for heparin rises as well. According to the American Heart Association Inc. (AHA), the majority of evidence on the prevalence and mortality of venous thromboembolism (VTE) comes from high-income countries, especially North America, according to a study published in the journal Burden of Thrombosis in 2016.
During the forecast period (2019–2027), the U.S. unfractionated heparin market is projected to develop at a CAGR of 4.5 percent.
Get Sample PDF Including COVID-19 Impact Analysis: https://www.coherentmarketinsights.com/insight/request-pdf/3187
Drivers
The U.S. unfractionated heparin market is expected to rise as a result of supportive government regulations.
Due to the beneficial regulatory environment, the U.S. unfractionated heparin market is predicted to grow significantly. As per the Medicare Prescription Source Benefit Manual: Chapter 6: 2016, the source (extraction of heparin) used for heparin processing must be used for a legally approved indication that aids in the diagnosis or treatment of a disease or an injury. Furthermore, a source cannot meet the criteria of a Part D source if it operates on medical instruments or machines and is not used with a medically-accepted indication of medicinal value on the body. A heparin flush is used to dissolve potential blood clots along an infusion line rather than to treat a patient with a medically approved indication. As a result, the use of heparin in this case is not medicinal but rather appropriate for the proper operation of sturdy medical equipment. Hence, when heparin is used in a heparin flush, it is not a Part D source.
The American Society of Health-System Pharmacists (ASHP) has released a guideline on the appropriate and efficient use of heparin in neonatal treatment in 2014, which was reviewed by the Council on Therapeutics and the Board of Directors.
Tailored Information as per niche requirement:
LIMITED TIME OFFER - Hurry Up!
Exclusive offer!!! Purchase the report at a discounted rate!!!
Get Discount For Buyers UPTO 30% OFF On Any Research Report
Buy Now with Discount for Premium Report 2021: https://www.coherentmarketinsights.com/promo/buynow/3187
Business growth is expected to be fueled by rising thrombosis cases and market leaders' acceptance of strategies such as mergers and acquisitions.
Due to an increase in cases of deep-vein thrombosis in the U.S., the demand is expected to expand (DVT). As per a survey conducted in 2018 by the National Center for Biotechnology Information (NCBI), 200,000 individuals in the U.S. experience venous thrombosis per year, with 50,000 cases involving pulmonary embolism. The annual occurrence of deep-vein thrombosis (DVT) is estimated to be 80 cases per 100,000, with a prevalence of lower-limb DVT of 1 case per 1,000 people.
Players' embrace of inorganic growth initiatives is also fueling business growth; for example, Eisai and Nichi-Iko (parent company of Sagent Pharmaceuticals, Inc.) signed a partnership agreement in September 2019. Eisai and Nichi-Iko want to use this arrangement to expand their pharmacy industry in China by introducing high-quality generic drugs. By bolstering its China-based generic market, Eisai will be able to serve a wider variety of medical needs in China.
Special Requirements?
We value your investment and offer customization as per your requirements.
Share your precise requirements @ https://www.coherentmarketinsights.com/insight/request-customization/3187
Key Players
Key companies contributing in the U.S. unfractionated heparin market are Sagent Pharmaceuticals, Inc., Baxter International Inc., Bayer AG, B. Braun Melsungen AG, and Pfizer, Inc.
Table of Contents
- Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Source
- Market Snippet, By Injection Type
- Market Snippet, By Disease Indication
- Coherent Opportunity Map (COM)
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Product Launch
- Acquisition and Collaboration Scenario
- Industry Trends
- Regulatory Scenario
- Pricing Analysis
- PEST Analysis
- PORTER’s Analysis
- U.S. Unfractionated Heparin Market, By Source, 2016 – 2027, (US$ Mn)
- Introduction
- Market Share Analysis, 2019 and 2027 (%)
- Y-o-Y Growth Analysis, 2017 – 2027
- Segment Trends
- Porcine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Bovine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- U.S. Unfractionated Heparin Market, By Injection Type, 2016 – 2027, (US$ Mn)
- Introduction
- Market Share Analysis, 2019 and 2027 (%)
- Y-o-Y Growth Analysis, 2017 – 2027
- Segment Trends
- IV Injection
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Subcutaneous Injection
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- U.S. Unfractionated Heparin Market, By Disease Indication, 2016 – 2027, (US$ Mn)
- Introduction
- Market Share Analysis, 2019 and 2027 (%)
- Y-o-Y Growth Analysis, 2017 – 2027
- Segment Trends
- Venous Thromboembolism
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Cardioversion of Atrial Fibrillation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Pulmonary Embolism & Arterial Embolism
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Competitive Landscape
- Heat Map Analysis
- Market Share Analysis
- Analyst Views
- Section
- References
- Research Methodology
- About Us and Sales Contact
Have a Look at Related Research Insights:
EUROPE HEPARIN MARKET ANALYSIS
INTRAVENOUS SOLUTIONS MARKET ANALYSIS
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
Editor Details
-
Company:
- Coherent Market Insights
-
Name:
- Nirav Gokani
- Email:
-
Telephone:
- +918849480752
- Website:
Related Links
- Website: U.S. Unfractionated Heparin Market
